SGLT2i effect on atrial fibrillation: A network meta-analysis of randomized controlled trials.
RCTs
SGLT2i
atrial fibrillation
network meta‐analysis
Journal
Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756
Informations de publication
Date de publication:
28 Jun 2024
28 Jun 2024
Historique:
revised:
04
06
2024
received:
04
12
2023
accepted:
06
06
2024
medline:
28
6
2024
pubmed:
28
6
2024
entrez:
28
6
2024
Statut:
aheadofprint
Résumé
Gliflozins are recommended as first-line treatment in patients with heart failure and/or cardiovascular comorbidities and are demonstrated to reduce atrial fibrillation (AF) occurrence. However, it is not well known which gliflozin yields the larger cardioprotection in terms of AF occurrence reduction. Hence, we aimed to compare data regarding AF recurrence associated with different gliflozins. An accurate search of online scientific libraries (from inception to June 1, 2023) was performed. Fifty-nine studies were included in the meta-analysis involving 108 026 patients, of whom 60 097 received gliflozins and 47 929 received placebo. Gliflozins provided a statistically significant reduction of AF occurrence relative to standard of care therapy in the overall population (relative risks [RR]: 0.8880, 95% CI: [0.8059; 0.9784], p = .0164) and in patients with diabetes and cardiorenal diseases (RR: 0.8352, 95% CI: [0.7219; 0.9663], p = .0155). Dapagliflozin significantly decreased AF occurrence as compared to placebo (0.7259 [0.6337; 0.8316], p < .0001) in the overall population, in patients with diabetes (RR: 0.2482, 95% CI: [0.0682; 0.9033], p = .0345), with diabetes associated with cardiorenal diseases (RR: 0.7192, 95% CI: [0.5679; 0.9110], p = .0063) and in the subanalysis including studies with follow-up ≥1 year (RR: 0.7792, 95% CI: [0.6508; 0.9330], p = .0066). No significant differences in terms of AF protection were found among different gliflozins. Dapagliflozin use was associated with significant reduction in AF risk as compared to placebo in overall population and patients with diabetes, whereas the use of other gliflozins did not significantly reduce AF occurrence.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Lippi G, Sanchis‐Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke. 2021;16(2):217‐221.
Santhanakrishnan R, Wang N, Larson MG, et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation. 2016;133(5):484‐492.
Olsson LG, Swedberg K, Ducharme A, et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction. J Am Coll Cardiol. 2006;47(10):1997‐2004.
Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio‐Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373‐498.
Rienstra M, Hobbelt AH, Alings M, et al. Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial. Eur Heart J. 2018;39(32):2987‐2996.
McDonagh TA, Metra M, Adamo M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627‐3639.
Fernandes GC, Fernandes A, Cardoso R, et al. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta‐analysis of 34 randomized controlled trials. Heart Rhythm. 2021;18(7):1098‐1105.
Zelniker TA, Bonaca MP, Furtado RHM, et al. Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE‐TIMI 58 trial. Circulation. 2020;141(15):1227‐1234.
Knobloch K, Yoon U, Vogt PM. Preferred reporting items for systematic reviews and meta‐analyses (PRISMA) statement and publication bias. J Cranio‐Maxillofacial Surg. 2011;39:91‐92.
Higgins JPTDJ, Altman DG. Chapter 16: special topics in statistics. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration; 2011.
Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise. Diabetes Care. 2010;33(10):2217‐2224.
Rosenstock J, Aggarwal N, Polidori D, et al. Dose‐ranging effects of canagliflozin, a sodium‐glucose cotransporter 2 inhibitor, as add‐on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35(6):1232‐1238.
Wilding JPH. Long‐term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156(6):405‐415.
Inagaki N, Kondo K, Yoshinari T, Maruyama N, Susuta Y, Kuki H. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled, 12‐week study. Diabetes, Obes Metab. 2013;15(12):1136‐1145.
Wilding JPH, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract. 2013;67:1267‐1282.
Lavalle‐González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56:2582‐2592.
Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF. Dapagliflozin add‐on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double‐blind, placebo‐controlled 102‐week trial. BMC Med. 2013;11:43. doi:10.1186/1741-7015-11-43
Rosenstock J, Seman LJ, Jelaska A, et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add‐on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes, Obes Metab. 2013;15(12):1154‐1160.
Cefalu WT, Leiter LA, de Bruin TWA, Gause‐Nilsson I, Sugg J, Parikh SJ. Dapagliflozin's effects on glycemia and cardiovascular risk factors in high‐risk patients with type 2 diabetes: a 24‐week, multicenter, randomized, double‐blind, placebo‐controlled study with a 28‐week extension. Diabetes Care. 2015;38(7):1218‐1227.
Ji L, Han P, Liu Y, et al. Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea. Diabetes, Obes Metab. 2015;17:23‐31.
Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes, Obes Metab. 2014;16(10):1016‐1027.
Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double‐blind, placebo‐controlled trial. Lancet Diabetes Endocrinol. 2014;2(5):369‐384.
Leiter LA, Cefalu WT, de Bruin TWA, Gause‐Nilsson I, Sugg J, Parikh SJ. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24‐week, multicenter, randomized, double‐blind, placebo‐controlled study with a 28‐week extension. J Am Geriatr Soc. 2014;62(7):1252‐1262.
Bode B, Stenlöf K, Harris S, et al. Long‐term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes. Diabetes, Obes Metab. 2015;17(3):294‐303.
Mathieu C, Herrera Marmolejo M, González González JG, et al. Efficacy and safety of triple therapy with dapagliflozin add‐on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes. Diabetes, Obes Metab. 2016;18:1134‐1137. doi:10.1111/dom.12737
Bailey CJ, Morales Villegas EC, Woo V, Tang W, Ptaszynska A, List JF. Efficacy and safety of dapagliflozin monotherapy in people with type 2 diabetes: a randomized double‐blind placebo‐controlled 102‐week trial. Diabetic Med. 2015;32(4):531‐541. doi:10.1111/dme.12624
Roden M, Merker L, Christiansen AV, et al. EMPA‐REG EXTEND™ MONO Investigators. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug‐naïve patients with type 2 diabetes: a double‐blind extension of a phase III randomized controlled trial. Cardiovasc Diabetol. 2015;14:154.
Kovacs CS, Seshiah V, Merker L, et al. Empagliflozin as add‐on therapy to pioglitazone with or without metformin in patients with type 2 diabetes mellitus. Clin Ther. 2015;37(8):1773‐1788.e1.
Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial. Diabetes, Obes Metab. 2015;17(10):936‐948.
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644‐657. doi:10.1056/NEJMoa1611925
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117‐2128.
Rosenstock J, Chuck L, González‐Ortiz M, et al. Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug‐naïve type 2 diabetes. Diabetes Care. 2016;39(3):353‐362.
Frías JP, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION‐8): a 28 week, multicentre, double‐blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4(12):1004‐1016.
Garg SK, Henry RR, Banks P, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med. 2017;377(24):2337‐2348.
Januzzi Jr., JL, Butler J, Jarolim P, et al. Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes. J Am Coll Cardiol. 2017;70(6):704‐712.
Søfteland E, Meier JJ, Vangen B, Toorawa R, Maldonado‐Lutomirsky M, Broedl UC. Empagliflozin as add‐on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin: a 24‐week randomized, double‐blind, parallel‐group trial. Diabetes Care. 2017;40(2):201‐209.
Grunberger G, Camp S, Johnson J, et al. Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: the VERTIS RENAL randomized study. Diabetes Ther. 2018;9(1):49‐66.
Neal B, Perkovic V, de Zeeuw D, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium‐glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care. 2015;38:403‐411. doi:10.2337/dc14-1237
Buse JB, Garg SK, Rosenstock J, et al. Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American in Tandem1 study. Diabetes Care. 2018;41(9):1970‐1980.
Rosenstock J, Frias J, Páll D, et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes, Obes Metab. 2018;20:520‐529.
Fioretto P, Del Prato S, Buse JB, et al. DERIVE Study Investigators. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): the DERIVE study. Diabetes, Obes Metab. 2018;20(11):2532‐2540.
Nassif ME, Windsor SL, Tang F, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE‐HF trial. Circulation. 2019;140(18):1463‐1476.
Butt JH, Docherty KF, Jhund PS, et al. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF. Eur J Heart Fail. 2022;24(3):513‐525.
Verma S, Mazer CD, Yan AT, et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA‐HEART cardiolink‐6 randomized clinical trial. Circulation. 2019;140(21):1693‐1702.
Perkovic V, Jardine MJ, Neal B, et al. CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295‐2306.
Pollock C, Stefánsson B, Reyner D, et al. Albuminuria‐lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double‐blind, placebo‐controlled trial. Lancet Diabetes Endocrinol. 2019;7(6):429‐441.
Dose Finding A. Study to assess the effect of LIK066 compared to placebo or empagliflozin in patients with type 2 diabetes mellitus and heart failure. 2019. https://www.clinicaltrials.gov/ct2/show/results/NCT03152552
Damman K, Beusekamp JC, Boorsma EM, et al. Randomized, double‐blind, placebo‐controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA‐RESPONSE‐AHF). Eur J Heart Fail. 2020;22(4):713‐722.
Heerspink HJL, Stefánsson BV, Correa‐Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436‐1446.
DETERMINE‐preserved—Dapagliflozin effect on exercise capacity using a 6‐minute walk test in patients with heart failure with preserved ejection fraction [serial online]. Accessed November 27, 2022. https://clinicaltrials. gov/ct2/show/NCT03877224.
This study tests empagliflozin in patients with chronic heart failure with preserved ejection fraction (HFpEF). The study looks at how far patients can walk in 6 minutes and at their heart failure symptoms (EMPERIAL‐perserved) [serial online]. Accessed November 27, 2022. https://clinicaltrials.gov/ct2/ show/NCT03448406.
Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451‐1461.
This study tests empagliflozin in patients with chronic heart failure with reduced ejection fraction (HFrEF). The study looks at how far patients can walk in 6 minutes and at their heart failure symptoms (EMPERIAL‐reduced) [serial online]. Accessed November 27, 2022. https://clinicaltrials.gov/ct2/ show/NCT03448419.
Jensen J, Omar M, Kistorp C, et al. Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: a double‐blinded, randomized, and placebo‐controlled trial. Am Heart J. 2020;228:47‐56.
Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413‐1424.
Cannon CP, Pratley R, Dagogo‐Jack S, et al. Cardiovascular outcomes with Ertugli‐flozin in type 2 diabetes. N Engl J Med. 2020;383:1425‐1435.
Kosiborod MN, Esterline R, Furtado RHM, et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID‐19 (DARE‐19): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021;9(9):586‐594.
DETERMINE‐reduced—Dapagliflozin effect on exercise capacity using a 6‐minute walk test in patients with heart failure with reduced ejection fraction [serial online]. Accessed November 27, 2022. https://clinicaltrials.gov/ ct2/show/NCT03877237.
Cherney DZI, Ferrannini E, Umpierrez GE, et al. Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment. Diabetes, Obes Metab. 2021;23(12):2632‐2642.
Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384(2):129‐139.
Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117‐128.
Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nature Med. 2022;28(3):568‐574.
Nassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nature Med. 2021;27(11):1954‐1960.
Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089‐1098.
Lee MMY, Brooksbank KJM, Wetherall K, et al. Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR‐DM‐HF). Circulation. 2021;143:516‐525.
Spertus JA, Birmingham MC, Nassif M, et al. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF‐HF remote, patient‐centered randomized trial. Nature Med. 2022;28(4):809‐813.
Katakami N, Mita T, Yoshii H, et al. Tofogliflozin long‐term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease: a 2‐year extension study of the UTOPIA trial. Cardiovasc Diabetol. 2023;22(1):143. doi:10.1186/s12933-023-01879-4
Cherney DZI, Ferrannini E, Umpierrez GE, et al. Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease. Diabetes, Obes Metab. 2023;25(6):1646‐1657.
Ouyang X, Wang J, Chen Q, Peng L, Li S, Tang X. Sodium‐glucose cotransporter 2 inhibitor may not prevent atrial fibrillation in patients with heart failure: a systematic review. Cardiovasc Diabetol. 2023;22(1):124. doi:10.1186/s12933-023-01860-1
Packer M, Anker SD, Butler J, Filippatos G, Zannad F. Effects of sodium‐glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol. 2017;2:1025‐1029.
Manolis AA, Manolis TA, Melita H, Manolis AS. Sodium‐glucose cotransporter type 2 inhibitors and cardiac arrhythmias. Trends Cardiovascul Med. 2023;33(7):418‐428.
Tian J, Zhang M, Suo M, et al. Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKα/TGF‐β/Smad signalling in type 2 diabetic rats. J Cell Mol Med. 2021;25:7642‐7659.
Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med. 2017;104:298‐310.
Ziyrek M, Dönmez E, Özcan S, et al. Effect of SGLT‐2 inhibitors as an add‐on therapy to metformin on P wave indices and atrial electromechanics in type 2 diabetes mellitus patients. Pacing Clin Electrophysiol. 2023;46(7):803‐810.
Abu‐Qaoud MR, Kumar A, Tarun T, et al. Impact of SGLT2 inhibitors on AF recurrence after catheter ablation in patients with type 2 diabetes. JACC: Clin Electrophysiol. 2023;9(10):2109‐2118.
Younis A, Arous T, Klempfner R, et al. Effect of sodium glucose cotransporter 2 inhibitors on atrial tachy‐arrhythmia burden in patients with cardiac implantable electronic devices. J Cardiovasc Electrophysiol. 2023;34(8):1595‐1604.